Foghorn Therapeutics (FHTX) EBITDA (2019 - 2026)

Foghorn Therapeutics' EBITDA history runs 8 years deep, the most recent figure standing at -$21.6 million for Q1 2026.

• On a quarterly basis, EBITDA rose 5.85% year-over-year to -$21.6 million in Q1 2026; TTM through Mar 2026 was -$85.0 million, a 12.68% increase from a year earlier, with the FY2025 full-year figure at -$86.4 million, up 15.87% from the prior year.
• EBITDA improved to -$21.6 million in Q1 2026 per FHTX's latest filing, from -$23.9 million in the prior quarter.
• Across five years, EBITDA topped out at -$17.1 million in Q3 2023 and bottomed at -$33.3 million in Q1 2023.
• The 5-year median for EBITDA is -$25.5 million (2023), against an average of -$25.6 million.
• Across the five-year window, EBITDA jumped 39.56% in 2023 and sank 39.64% in 2024, its largest moves.
• Year by year, EBITDA stood at -$31.9 million in 2022, then rose by 20.16% to -$25.5 million in 2023, then rose by 5.71% to -$24.0 million in 2024, then grew by 0.53% to -$23.9 million in 2025, then rose by 9.65% to -$21.6 million in 2026.
• Per Business Quant, the three latest FHTX EBITDA figures stand at -$21.6 million (Q1 2026), -$23.9 million (Q4 2025), and -$18.5 million (Q3 2025).